Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Retroperitoneal fibrosis refers to a group of diseases characterized by hyperplasia of the
fibrosclerotic tissues in the retroperitoneal space, which can compress the surrounding
ureters and inferior vena cava and cause serious complications such as aortic aneurysm, renal
failure, and even death. The lesion is diffuse and difficult to resect. corticosteroid is the
first-line medication, but the recurrence rate of the disease is high, especially after dose
reduction of corticosteroid. Therefore, the combined use of immunosuppressants is very
important in preventing disease recurrence and reducing the toxic and side effects of
long-term corticosteroid. Sirolimus plays dual roles in inhibiting lymphocyte activation and
fibroblast proliferation. It is inferred from its mechanism that sirolimus is a good
potential treatment option for idiopathic retroperitoneal fibrosis. Therefore, we conducted
this RCT on patients with idiopathic retroperitoneal fibrosis to determine the efficacy and
safety of sirolimus.